Print

Purpose

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Plaque psoriasis for at least 6 months - Moderate to severe disease - Candidate for phototherapy or systemic therapy

Exclusion Criteria

  • Other forms of psoriasis - History of recent infection - Prior exposure to BMS-986165 or active comparator Other protocol defined inclusion/exclusion criteria could apply

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
BMS-986165 		BMS-986165 oral administration
  • Drug: BMS-986165
    Specified dose on specified days
Placebo Comparator
Placebo 		Placebo oral administration
  • Other: Placebo
    Specified dose on specified days
Active Comparator
Active comparator 		Active comparator oral administration
  • Drug: Apremilast
    Specified dose on specified days

More Details

Status
Completed
Sponsor
Bristol-Myers Squibb

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.